These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33673305)

  • 21. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
    Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
    Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.
    Walko CM; McLeod H
    Pharmacogenomics; 2012 Apr; 13(6):691-7. PubMed ID: 22515611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
    de Vries Schultink AHM; Huitema ADR; Beijnen JH
    Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
    Jansen LE; Teft WA; Rose RV; Lizotte DJ; Kim RB
    Breast Cancer Res Treat; 2018 Oct; 171(3):701-708. PubMed ID: 29980881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
    Henderson SL; Teft WA; Kim RB
    BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
    Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort.
    Gryn SE; Teft WA; Kim RB
    Pharmacogenet Genomics; 2014 Jul; 24(7):367-9. PubMed ID: 24915025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer.
    Helland T; Alsomairy S; Lin C; Søiland H; Mellgren G; Hertz DL
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33805613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen.
    Saghafi F; Salehifar E; Janbabai G; Zaboli E; Hedayatizadeh-Omran A; Amjadi O; Moradi S
    Biomed Rep; 2018 Nov; 9(5):446-452. PubMed ID: 30345040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
    Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
    [No Abstract]   [Full Text] [Related]  

  • 35. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
    J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites.
    Chen Y; Marcath LA; Eliassen FM; Lende TH; Soiland H; Mellgren G; Helland T; Hertz DL
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34199712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.
    Brauch H; Schroth W; Eichelbaum M; Schwab M; Harbeck N;
    Breast Care (Basel); 2008; 3(1):43-50. PubMed ID: 20824020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
    Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Suc E; Sillet-Bach I; Filleron T; Roché H; Chatelut E; White-Koning M; Thomas F
    Clin Pharmacol Ther; 2019 Sep; 106(3):585-595. PubMed ID: 30786012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
    Del Re M; Citi V; Crucitta S; Rofi E; Belcari F; van Schaik RH; Danesi R
    Pharmacol Res; 2016 May; 107():398-406. PubMed ID: 27060675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.